[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-dysfunction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,81,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100346454","cardiac-dysfunction-in-childhood-cancer-survivors-100346454",false,"NCT03790943","Cardiac Dysfunction in Childhood Cancer Survivors","Prospective Single Center Cohort Study for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors","Cardio-Onco","This prospective cohort study is nested within the Childhood Cancer Registry (ChCR), a national, population-based cancer registry that includes all children and adolescents in Switzerland who were diagnosed with cancer at age 0-20 years. It includes patients diagnosed with leukemia, lymphoma, central nervous system tumors, and malignant solid tumours or Langerhans cell histiocytosis. Childhood cancer survivors have survived at least 5 years from cancer diagnosis.\n\nInclusion Criteria:\n\n* Registered in the ChCR\n* Formerly treated at the Department of Pediatric Hematology\u002FOncology of one of five participating centers\n* Treated with any chemotherapy and\u002For chest radiation\n* Survived ≥ 5 years since most recent cancer diagnosis (primary cancer, relapse(s), secondary cancer) at time of examination\n* Diagnosed at age ≤ 20 years\n* ≥ 18 years of age at time of study participation\n* Resident in Switzerland\n* Written informed consent\n\nExclusion Criteria:\n\n* Study participants will be excluded if they do not meet the above mentioned inclusion criteria or refuse to participate in the study.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle tracking echocardiography as novel echocardiographic technique compared to conventional echocardiography.",[25,26,27],"Cardiac Dysfunction","Cardiovascular Diseases","Childhood Cancer",[29,30,31,32,33,34],"Childhood cancer survivors","Late effects","Cardiotoxicity","Chemotherapy","Anthracyclines","Radiation","RECRUITING","2026-05-27",{"date":38,"type":39},"2026-05-29","ACTUAL",{"date":41,"type":39},"2018-02-13",{"date":43,"type":21},"2029-04-23",{"name":45,"class":46},"University of Bern","OTHER",6,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100601432","phase-4-efficacy-and-safety-trials-of-yangxinshi-tablets-in-the-treatment-of-patients-with-coronary-heart-disease-complicated-by-cardiac-dysfunction-100601432","NCT07110415","Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction","A Randomized Controlled Trial of the Efficacy and Safety of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction","HEARTPOWER","Inclusion Criteria:\n\n1. For inpatients diagnosed with coronary heart disease (including acute coronary syndrome and chronic coronary syndrome), it is up to the doctor to decide whether to undergo revascularization and what kind of revascularization to use.\n2. Patients aged between 40 and 80 years (inclusive), regardless of sex;\n3. Patients with NYHA cardiac function classes II-IV;\n4. Patients with NT-proBNP \\> 125 pg\u002FmL (or BNP\\>35 pg\u002FmL);\n5. The syndrome differentiation in traditional Chinese medicine conforms to chest obstruction (qi deficiency and blood stasis syndrome)\n6. Patients who voluntarily participated and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with STEMI within 3 days;\n2. Patients at extremely high risk of NSTEMI (hemodynamic instability, cardiogenic shock, new-onset heart failure or aggravated heart failure, severe ventricular arrhythmia)\n3. Patients with acute myocardial infarction complicated with cardiogenic shock, mechanical complications, respiratory failure and other multiple organ failure;\n4. Patients with severe liver dysfunction (transaminase levels more than three times the upper limit of normal), renal insufficiency (eGFR \\\u003C 30mL\u002Fmin\u002F1.73m2), acute infectious diseases, and mental disorders;以上翻译结果来自有道神经网络翻译（YNMT）· 通用场景\n5. Patients with drug-resistant hypertension (systolic blood pressure ≥180 mmHg and\u002For diastolic blood pressure ≥110 mmHg);\n6. Pregnant or lactating women, or those planning pregnancy during the study period;\n7. Patients who cannot tolerate 3 months of dual antiplatelet therapy;\n8. Patients with allergic reactions or abnormal drug reactions to the study drug or any of its excipients;\n9. Patients who have regularly taken Yangxinshi tablets and similar traditional Chinese medicine, Chinese patent medicine or traditional Chinese medicine decoction with the same curative effectin the past month;\n10. Patients who have participated in other clinical drug trials within the last three months;\n11. Patients with malignant tumors and other pathological conditions with an expected survival of less than 3 years;\n12. Patients whom the investigator deems unsuitable for participating in the clinical trial.","40 Years","80 Years",{"count":59,"type":21},2708,"INTERVENTIONAL",[62],"PHASE4","A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction.",[65,25],"Coronary Heart Disease",[67,68,69],"Yangxinshi","Coronary heart disease","Cardiac dysfunction","2025-11-20",{"date":72,"type":39},"2025-11-25",{"date":74,"type":39},"2025-11-06",{"date":76,"type":21},"2030-12-31",{"name":78,"class":79},"SPH Qingdao Growful Pharmacetical Co.,Ltd","INDUSTRY",96,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":100,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100605065","cardiovascular-complications-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100605065","NCT07157670","Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.","ALLOCARDIOTOX","Inclusion Criteria:\n\n* Age ≥ 15 years\n* Informed about the study and without objection to participation (or with consent from legal guardians)\n* Undergoing allogeneic HSCT\n\nExclusion Criteria:\n\n* Patient not followed up at the participating center\n* Pregnant or breastfeeding women\n* Patient not affiliated with social security\n* Patient under guardianship, curatorship, or legal protection","15 Years",{"count":90,"type":21},400,"Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood.\n\nIt is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation.\n\nThis multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.",[31,93,94,95,96,25,97,98,99],"DPP3","HSCT","Allogeneic Hematopoietic Stem Cell Transplantation","ACS - Acute Coronary Syndrome","Arrythmia, Cardiac","Pulmonary Hypertension","Machine Learning",[93,94,31,101,99],"Allogeneic hematopoietic stem cell transplantation","NOT_YET_RECRUITING","2025-09-02",{"date":105,"type":39},"2025-09-05",{"date":107,"type":21},"2025-09-15",{"date":109,"type":21},"2028-09-15",{"name":111,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":60,"phases":121,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100489935","prognostic-role-of-the-uremic-toxin-indoxyl-sulfate-on-vascular-and-cardiac-functions-during-acute-kidney-injury-100489935","NCT05659589","Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury","VASC-AKI","Inclusion Criteria:\n\n* Age over 18 years old.\n* Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.\n* Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.\n* AKI from functional or organic aetiology\n\nExclusion Criteria:\n\n* Patients with severe CKD (GFR\\\u003C45ml\u002Fmin\u002F1.73 m2) or with kidney transplants.\n* Patients with AKI from septic or obstructive aetiology.\n* Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity.\n* Patients with sepsis or blood inflammation.\n* Patients with severe chronic cardia dysfunction.\n* Patients with arrhythmia or complete heart block.\n* Patients with peripheral artery occlusive disease.\n* Pregnancy.\n* Patients on palliative care.",{"count":120,"type":21},105,[122],"NA","Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown.\n\nThe purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.",[125,126,127,25,128],"Acute Kidney Injury","Uremic; Toxemia","Vascular Dysfunction","Cardiovascular Prognosis",[125,126,130,131,132],"vascular dysfunction","cardiac dysfunction","cardiovascular prognosis","2025-05-22",{"date":135,"type":39},"2025-05-28",{"date":137,"type":39},"2022-12-13",{"date":139,"type":21},"2026-06",{"name":141,"class":46},"Centre Hospitalier Universitaire, Amiens",1]